Health Canada approval of new ALS drug allows Canadians to get access first [Globe and Mail, The (Toronto, Canada)]
Amylyx Pharmaceuticals, Inc. (AMLX)
Company Research
Source: Globe and Mail, The
Log in or create a free account to listen to this article. Health Canada has become the first regulator in the world to approve a new amyotrophic lateral sclerosis (ALS) drug, only the third therapy for treatment of the fatal motor neuron condition to be authorized in 20 years. Amylyx Pharmaceuticals, based in Massachusetts, announced the decision Monday, saying the approval was made with the condition the company will provide Health Canada with further evidence of the drug's safety and efficacy once a larger trial is completed this summer. ALS patients and researchers celebrated the news, highlighting how few treatment options exist for those living with the disease, which progressively robs people of their ability to move, speak, swallow and breathe. “Anything that can slow the progression of this disease and allow people to retain their function longer is so significant,” said Tammy Moore, chief executive officer of the ALS Society of Canada. Justin Klee, co-founder and
Show less
Read more
Impact Snapshot
Event Time:
AMLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMLX alerts
High impacting Amylyx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMLX
News
- Investigation Alert Amylyx, Hut 8, Xponential Fitness, and iRhythm Technologies: Submit Your Information Now to Johnson Fistel, LLPGlobeNewswire
- The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) had its price target lowered by analysts at Robert W. Baird from $4.00 to $3.00. They now have a "neutral" rating on the stock.MarketBeat
- Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome [Yahoo! Finance]Yahoo! Finance
AMLX
Earnings
- 2/22/24 - Miss
AMLX
Sec Filings
- 4/18/24 - Form 4
- 4/18/24 - Form 4
- 4/18/24 - Form 4
- AMLX's page on the SEC website